The startup Moveo, founded by Vladimir Jeftović, is developing simultaneously in two directions: in the field of healthcare, as well as advanced AI analytics and optimization tools. In the medical field, the company based in Serbia, develops tools for the prevention of neurological complications caused by diabetes and for the improvement of the quality of life for people with diabetes.

Our company is a startup built around a core idea, as Vladimir Jeftović explains. "Our goal is to leverage modern technology to make a difference initially in healthcare by democratizing preventive medicine, and later in small businesses, enabling them to access high-quality data analysis similar to larger teams. As a startup, we often work with small datasets but big ideas, frequently simulating data to refine our algorithms. In this process, utilizing AI and high-performance computing proves highly beneficial", Vladimir Jeftović states.

The solution aims to help with earlier detection and tracking of diabetic neuropathy, which is nerve damage associated with diabetes mellitus. Diabetic neuropathy has the potential to affect any organ system and can cause a range of symptoms, from motor changes, numbness, pain, to urinary symptoms, and many others. Vladimir states, "We already conducted a clinical study in partnership with the Institute of Rheumatology at the Clinical Center Serbia. This feasibility study compared our technology with the current gold standard for detecting neuropathy".

The Moveo device employs a machine learning algorithm to identify and monitor diabetic neuropathy. It features four sensors placed on the back of the hands and feet that measure movement signals and collect data. Vladimir explains, "We published a scientific paper in a journal where we demonstrated very high accuracy for a feasibility trial of 90% compared to the gold standard, electroneuromyography."